The GSTK1 Knockout SK-HEP-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal human hepatic adenocarcinoma cell population in which the GSTK1 gene has been disrupted. This polyclonal knockout pool retains the genetic heterogeneity inherent to non-clonal editing, making it suitable for studying average gene disruption effects in a mixed population. CRISPR/Cas9-mediated gene disruption introduces loss-of-function alterations at the GSTK1 locus, enabling researchers to interrogate glutathione S-transferase kappa 1 function in a liver cancer-derived cellular context.
The SK-HEP-1 cell line is a well-established human hepatic adenocarcinoma model with epithelial morphology, commonly employed in liver cancer research. Derived from the ascites of a patient with liver adenocarcinoma, these cells exhibit features relevant to hepatocellular carcinoma, including deregulated oxidative stress responses and drug metabolism pathways. SK-HEP-1 cells express key components of the antioxidant defense system and are widely used to investigate mechanisms of chemoresistance and xenobiotic detoxification. This host background provides a pathophysiologically relevant environment for interrogating GSTK1-dependent functions.
GSTK1 encodes a peroxisomal glutathione S-transferase that catalyzes the conjugation of reduced glutathione (GSH) to electrophilic compounds, facilitating their detoxification and protecting against oxidative stress. This enzyme is transcriptionally regulated by NRF2 (NFE2L2), which is itself controlled by KEAP1-mediated degradation under basal conditions. Upon oxidative stress or xenobiotic exposure, NRF2 dissociates from KEAP1, accumulates, and promotes expression of GSTK1 and other antioxidant genes. GSTK1 activity reduces reactive oxygen species and generates conjugated glutathione metabolites, which can be exported by multidrug resistance proteins. Thus, GSTK1 functions as a critical downstream effector in the NRF2?CKEAP1 pathway, interacting with glutathione and peroxisomal matrix proteins to maintain cellular redox homeostasis.
Disruption of GSTK1 in SK-HEP-1 cells impairs the glutathione-dependent detoxification axis, sensitizing cells to electrophilic and oxidative insults. Given the high basal oxidative stress and drug resistance mechanisms in hepatic adenocarcinoma, this polyclonal knockout model enables the dissection of GSTK1??s contribution to chemoresistance, particularly against agents such as cisplatin. Loss of GSTK1 may attenuate NRF2-driven protective responses, leading to elevated reactive oxygen species and enhanced drug sensitivity. Moreover, the peroxisomal localization of GSTK1 suggests additional roles in lipid metabolism and peroxisomal redox balance, which can be explored in this knockout context. This model thus provides a powerful tool to investigate how peroxisomal GSTs influence cancer cell survival and therapeutic response.
The GSTK1 Knockout SK-HEP-1 Polyclonal Cells are ideally suited for a range of functional studies, including assessment of cell viability following cisplatin treatment, measurement of total glutathione levels, detection of intracellular reactive oxygen species, and western blotting for GSTK1 and NRF2 target gene expression. Researchers can employ this model for drug sensitivity screening to identify compounds whose efficacy is modulated by GSTK1-dependent detoxification. Additionally, RT-qPCR analysis of NRF2 target genes can reveal transcriptional compensation mechanisms. The polyclonal population format supports experiments that average clonal variation, such as pooled CRISPR screens or bulk biochemical assays. For further details, customization options, or bulk ordering, please contact Ascent Research.
